Payment overview · 2025
General Payments
$804.17
39 reported records · 9 companies
Healthcare provider profile · identity verified
Mohamed A Sabbagh, MD
Allopathic & Osteopathic Physicians|Family Medicine · WESTON, WV · NPI 1124349493
Verified facts
What the public records show
CMS Open Payments records show Mohamed A Sabbagh, MD received $804.17 in general payments during 2025 across 39 reported records.
CSL Behring accounted for 29.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 488 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CSL Behring | Unresolved — no canonical attribution shown | $238.80 | 29.7% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $139.49 | 17.4% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $134.93 | 16.8% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $104.23 | 13.0% | 6 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $71.74 | 8.9% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $44.44 | 5.5% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $26.16 | 3.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.88 | 3.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.50 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $804.17 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Andembry Normalized: andembry |
Biological | CSL Behring | $194.30 | 7 | 2025 |
Source payment records
|
|||||
| Haegarda Normalized: haegarda |
Biological | CSL Behring | $112.90 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $104.23 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $93.94 | 6 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $71.74 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $68.04 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $51.27 | 3 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $44.44 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.99 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.99 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.88 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 488 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 87 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
91 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
87 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
488 | 85 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 823 | 215 |
| Metoprolol Tartrate | Metoprolol Tartrate | 636 | 214 |
| Lisinopril | Lisinopril | 531 | 139 |
| Gabapentin | Gabapentin | 498 | 54 |
| Eliquis | Apixaban | 488 | 85 |
| Clopidogrel | Clopidogrel Bisulfate | 473 | 147 |
| Furosemide | Furosemide | 462 | 147 |
| Tamsulosin Hcl | Tamsulosin Hcl | 448 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 438 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 391 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 374 | 109 |
| Losartan Potassium | Losartan Potassium | 346 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 311 | 73 |
| Sertraline Hcl | Sertraline Hcl | 309 | 37 |
| Omeprazole | Omeprazole | 307 | 57 |
| Metformin Hcl | Metformin Hcl | 291 | 70 |
| Finasteride | Finasteride | 261 | 37 |
| Donepezil Hcl | Donepezil Hcl | 213 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 204 | 69 |
| Quetiapine Fumarate | Quetiapine Fumarate | 203 | 20 |
| Carvedilol | Carvedilol | 198 | 52 |
| Jardiance | Empagliflozin | 189 | 21 |
| Potassium Chloride | Potassium Chloride | 187 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 178 | 32 |
| Montelukast Sodium | Montelukast Sodium | 177 | 37 |
| Nystatin | Nystatin | 176 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 163 | 33 |
| Famotidine | Famotidine | 160 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 145 | 37 |
| Trazodone Hcl | Trazodone Hcl | 144 | 32 |
| Buspirone Hcl | Buspirone Hcl | 140 | 26 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 134 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 39 |
| Allopurinol | Allopurinol | 116 | 29 |
| Memantine Hcl | Memantine Hcl | 106 | 18 |
| Spironolactone | Spironolactone | 102 | 29 |
| Simvastatin | Simvastatin | 99 | 23 |
| Tramadol Hcl | Tramadol Hcl | 99 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 95 | 40 |
| Latanoprost | Latanoprost | 92 | suppressed |
| Brilinta | Ticagrelor | 91 | 25 |
| Glipizide | Glipizide | 90 | 19 |
| Baclofen | Baclofen | 89 | 15 |
| Farxiga | Dapagliflozin Propanediol | 87 | 15 |
| Albuterol Sulfate | Albuterol Sulfate | 83 | 22 |
| Cefuroxime | Cefuroxime Axetil | 82 | 51 |
| Atenolol | Atenolol | 78 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 77 | 50 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 21 |
| Divalproex Sodium | Divalproex Sodium | 76 | suppressed |
| Xarelto | Rivaroxaban | 75 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 74 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 74 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 44 |
| Azithromycin | Azithromycin | 69 | 39 |
| Metformin Hcl Er | Metformin Hcl | 68 | suppressed |
| Entresto | Sacubitril/Valsartan | 66 | 25 |
| Ozempic | Semaglutide | 66 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 22 |
| Nitroglycerin | Nitroglycerin | 63 | 42 |
| Torsemide | Torsemide | 61 | 20 |
| Digoxin | Digoxin | 58 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 28 |
| Cephalexin | Cephalexin | 56 | 32 |
| Novolin R | Insulin Regular, Human | 55 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | suppressed |
| Meloxicam | Meloxicam | 54 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 35 |
| Risperidone | Risperidone | 52 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 11 |
| Glimepiride | Glimepiride | 51 | suppressed |
| Methylprednisolone | Methylprednisolone | 51 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 17 |
| Tradjenta | Linagliptin | 51 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 50 | 12 |
| Sucralfate | Sucralfate | 49 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | 15 |
| Ssd | Silver Sulfadiazine | 48 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 46 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Prednisone | Prednisone | 43 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Ibuprofen | Ibuprofen | 42 | 14 |
| Lorazepam | Lorazepam | 42 | 12 |
| Silver Sulfadiazine | Silver Sulfadiazine | 39 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 26 |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 17 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Xifaxan | Rifaximin | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Creon | Lipase/Protease/Amylase | 31 | suppressed |
| Enulose | Lactulose | 31 | suppressed |
| Nystop | Nystatin | 31 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Olanzapine | Olanzapine | 30 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 25 |
| Atropine Sulfate | Atropine Sulfate | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Erythromycin | Erythromycin Base | 25 | suppressed |
| Insulin Aspart | Insulin Aspart | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Novolog | Insulin Aspart | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Trimethoprim | Trimethoprim | 23 | suppressed |
| Humulin R | Insulin Regular, Human | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 18 | 17 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Admelog | Insulin Lispro | 17 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Levemir | Insulin Detemir | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Cimetidine | Cimetidine | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 14 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Probenecid | Probenecid | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Aristada | Aripiprazole Lauroxil | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Ursodiol | Ursodiol | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Rhopressa | Netarsudil Mesylate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Daptomycin | Daptomycin | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $804.17 · 39 records | CSL Behring | AIRSUPRA, Andembry, Assure WCD, BREZTRI, CAPVAXIVE, ELIQUIS, FARXIGA, Haegarda, Kerendia, LifeVest, Ozempic, Rybelsus, VERQUVO, Wegovy, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error